Biotech entity
Coverage clusters in pharma, which accounts for 3 of those 4, with the remainder spread across 1 other category. AlloMap Heart is the most frequent co-covered peer, appearing in 1 of the 4 tracked stories. Across a 42-day span, the pace is roughly 0.7 stories per week.
Last mentioned: Aug 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Coverage clusters in pharma, which accounts for 3 of those 4, with the remainder spread across 1 other category. AlloMap Heart is the most frequent co-covered peer, appearing in 1 of the 4 tracked stories. Across a 42-day span, the pace is roughly 0.7 stories per week. They are corroborated in line with the beat average, carrying 2.3 original sources each against 2.3 for the same window. Their average consequence score of 6.8 runs above the beat's 5.9 for that window. Abbott Laboratories appears in 4 tracked Biotech stories published from July 17, 2026 through August 27, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 215 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Abbott Laboratories. Shared-story counts are live from our verified record — not editorial picks.
Investigation remains unresolved
SecurityWeek reports no known cybercrime group has claimed responsibility; full scope, nature, and financial impact remain unknown.
Disclosure and market reaction
Company announces global operational disruption, including order processing and shipping systems; shares fall about 4% in morning trading. Evercore ISI estimates a 600-700 bps Q3 revenue impact if recovery mirrors Stryker's three-week timeline.
Cyber incident detected
Boston Scientific detects a cybersecurity incident affecting some IT systems.
Boston Scientific's August 25 cyberattack has disrupted global order processing and shipping, creating clinical and financial uncertainty for the medical device maker. Evercore ISI estimates a 600-700 basis point hit to Q3 revenue if recovery follows Stryker's roughly three-week timeline. The company has not yet determined whether the incident will be material.
Source: SecurityWeek
CareDx surged 35% after Medicare finalized coverage for transplant rejection tests, unlocking a major revenue opportunity. AtaiBeckley soared 33% following Eli Lilly's $3.8B acquisition, while Abbott raised its outlook and Apollomics extended its weekly rally to over 60% on its cancer drug candidate.
Source: rttnews.com · finanznachrichten.de
Abbott Laboratories reported Q2 revenue of $12.59 billion (+13% YoY), beating estimates and raising its full-year EPS guidance. Analysts hiked price targets in response, with BTIG going to $134, reflecting confidence in its diversified healthcare portfolio and pipeline. UnitedHealth also delivered a massive EPS beat, but Abbott’s medtech and diagnostics momentum carries particular relevance for the biopharma sector.
Source: benzinga.com
Abbott’s newly acquired oncology diagnostics from Exact Sciences—Cologuard and Oncotype DX—are offsetting COVID testing declines and powering a Q2 earnings beat. The company lifted its full-year 2026 adjusted EPS target, highlighting the value of high-margin, recurring precision testing businesses.
Source: businesstimes.com.sg · health.economictimes.indiatimes.com
Abbott Laboratories is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
